仁和药业成立于1996年12月4日，1996年12月10日在深圳证券交易所上市，注册地址为江西省宜春市，办 公地址为江西省南昌市。公司是知名的医药企业，拥有完善的产品线和品牌优势，在中药及健康相关产品 领域具有较高的知名度。 公司主营业务为生产、销售中西药、原料药及健康相关产品，涵盖口服固体制剂、口服液体制剂等多种剂 型药品以及健康相关产品。所属申万行业为医药生物 - 中药Ⅱ - 中药Ⅲ，所属概念板块包括工业大麻、医 药电商等。 经营业绩：营收行业21，净利润行业18 2025年三季度，仁和药业营业收入28.33亿元，行业排名21/69，行业第一名白云山达616.06亿元，第二名云 南白药306.54亿元，行业平均数为37.55亿元，中位数为14.62亿元。主营业务构成中，药品13.88亿元占比 70.25%，健康相关产品5.49亿元占比27.79%，其他业务产品3857.31万元占比1.95%。当期净利润4.69亿 元，行业排名18/69，行业第一名云南白药47.89亿元，第二名白云山33.98亿元，行业平均数为4.47亿元， 中位数为8367.73万元。 资产负债率低于同业平均，毛利率低于同业平均 偿债能 ...

Core Viewpoint - Renhe Pharmaceutical's stock price has shown fluctuations, with a recent decline of 2.00% on September 19, 2023, and a total market capitalization of 8.918 billion yuan [1] Group 1: Stock Performance - Year-to-date, Renhe Pharmaceutical's stock price has increased by 13.55%, but it has seen a decline of 0.62% over the last five trading days and 4.21% over the last twenty days [2] - The stock has experienced a 17.53% increase over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.962 billion yuan, with 770 million yuan distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Renhe Pharmaceutical was 104,400, a decrease of 2.76% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with both increasing their holdings compared to the previous period [3]

Core Viewpoint - Renhe Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 15.51%, reflecting strong market interest and performance in the pharmaceutical sector [1][2]. Company Overview - Renhe Pharmaceutical, established on December 4, 1996, and listed on December 10, 1996, is located in Nanchang, Jiangxi Province. The company specializes in the production and sale of traditional Chinese and Western medicines, raw materials, and health-related products [1]. - The company's revenue composition includes 70.25% from pharmaceuticals, 27.79% from health-related products, and 1.95% from other business products [1]. Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% compared to the previous year [2]. - The company has distributed a total of 1.962 billion yuan in dividends since its A-share listing, with 770 million yuan distributed over the last three years [3]. Shareholder Information - As of June 30, 2025, Renhe Pharmaceutical had 104,400 shareholders, a decrease of 2.76% from the previous period. The average number of tradable shares per shareholder increased by 2.84% to 12,748 shares [2]. - Major shareholders include Hong Kong Central Clearing Limited, which holds 11.4865 million shares, and Southern CSI 1000 ETF, holding 10.3367 million shares, both of which have increased their holdings [3].

Company Overview - Renhe Pharmaceutical Co., Ltd. is located in Nanchang, Jiangxi Province, and was established on December 4, 1996, with its listing date on December 10, 1996 [1] - The company primarily engages in the production and sales of traditional Chinese medicine, Western medicine, raw materials, and health-related products, with a revenue composition of 70.25% from pharmaceuticals, 27.79% from health-related products, and 1.95% from other business products [1] Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% year-on-year [2] - The company has cumulatively distributed 1.962 billion yuan in dividends since its A-share listing, with 770 million yuan distributed over the past three years [3] Stock Market Activity - As of September 1, Renhe Pharmaceutical's stock price increased by 2.09% to 6.35 yuan per share, with a trading volume of 150 million yuan and a turnover rate of 1.80%, resulting in a total market capitalization of 8.89 billion yuan [1] - The stock has seen a year-to-date increase of 13.19%, a decline of 3.93% over the last five trading days, a rise of 6.37% over the last 20 days, and an increase of 14.21% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on August 21 [1] Shareholder Information - As of June 30, 2025, Renhe Pharmaceutical had 104,400 shareholders, a decrease of 2.76% from the previous period, with an average of 12,748 circulating shares per shareholder, an increase of 2.84% [2] - Major shareholders include Hong Kong Central Clearing Limited, holding 11.4865 million shares, and Southern CSI 1000 ETF, holding 10.3367 million shares, both of which have increased their holdings compared to the previous period [3]

Core Viewpoint - Renhe Pharmaceutical's stock price has experienced a decline, reflecting challenges in revenue and profit despite a significant increase in cash flow from operating activities [1] Financial Performance - As of August 25, 2025, Renhe Pharmaceutical's stock price was 6.61 yuan, down 0.04 yuan or 0.60% from the previous trading day [1] - The company reported a revenue of 1.975 billion yuan for the first half of 2025, a year-on-year decrease of 16.46% [1] - Net profit attributable to shareholders was 290 million yuan, down 13.87% year-on-year [1] - The net cash flow from operating activities was 671 million yuan, showing a significant increase of 86.14% year-on-year [1] Market Activity - On August 25, 2025, the net inflow of main funds was 10.84 million yuan, accounting for 0.12% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds was 43.34 million yuan, representing 0.49% of the circulating market value [1] Business Strategy - Renhe Pharmaceutical focuses on the production and sales of traditional Chinese and Western medicines, raw materials, and health-related products, implementing a "pharmaceutical + health" dual-drive strategy [1]